Ethical Concerns Block Patents of Useful Embryonic Advances
By Antonio Regelado and Meera Louis,
The Wall Street Journal
| 08. 20. 2001
As the science of cloning and embryonic stem cells advances at a
breathtaking pace, universities and companies are seeking sweeping
patent claims over the new technologies. In the US , patent applications
in these two areas have jumped 300% in just the last year.
But ethical prohibitions embodied in patent law in the US and Europe
are preventing scientists from securing patents on some pioneering
biological inventions.
At issue in the US is the 13th Amendment to the Constitution, which
abolished slavery. Patent documents show that the legal prohibition
against owning humans has complicated efforts by Geron Corp. and closely
held Advanced Cell Technology Inc. to patent medical uses of human
cloning technology.
On the other side of the Atlantic, where mistrust of biotechnology
runs deeper, the European Patent Office has put the whole field of
embryonic stem cells on hold. Christian Gugerell, director of biotechnology
at the European Patent Office, says his examiners are delaying issuing
patents related to embryonic stem cells until an ethics committee
established by the European Commission issues recommendations on topics
that include the definition...
Related Articles
By Carissa Wong, New Scientist | 07.08.2026
Healthy lambs have been born via an experimental form of in vitro fertilisation (IVF) that coaxes highly immature eggs to become mature ones in the lab. This is the first time the approach has been demonstrated in a large animal...
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...